August 21, 2015
According to the Scottish Daily Record and the Scottish Information Services Division, it is.
It is expected that there will be a 33% rise in cancer cases over the next 12 years as the country’s population ages, with a predicted increase in cases from 30,500 to 40,000 by 2027. Lung cancer patient numbers in particular are likely to soar, the report says and is predicted to continue to be the most common cancer in Scotland in 2023-2027, with the number of new cases projected to increase by 20% between 2008-2012 and 2023-2027. This reflects historical levels of smoking in the population.
Health Secretary Shona Robison said: “Lifestyle changes have a big part to play. Drinking less alcohol, quitting smoking, exercising more and eating healthily all play a part in decreasing cancer risk.”
However as the rate of cancer cases is set to rise rapidly, early detection has only seen a 1.5% increase for lung, breast and colorectal cancers over the past 5 years.
Macmillan Cancer Support’s General Manager in Scotland, Janice Preston, said: “….Early diagnosis not only increases chances of survival but can mean less invasive treatment, which can offer people a better recovery and quality of life after their treatment is over.”
Scotland announced the ‘Detect Cancer Early Programme’ in 2012 – the Early Lung Cancer Detection Study (ECLS) is a key element of that programme.
The ECLS Study is the largest randomised trial for the early detection of lung cancer using biomarkers .The ECLS study uses the EarlyCDT-lung blood test. See www.eclsstudy.org for more information.
Daily Record http://bit.ly/1hO7Rhm
ISD – Detect Cancer Early Staging Data – http://bit.ly/1K9VDus
ECLS Study – http://www.eclsstudy.org/
Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).
These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.
By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.